NCT02236000
Breast Cancer Type: HER2+
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Active, not recruiting
Phase 1|Phase 2
Drug Category: Therapeutic Antibody, Tyrosine-Kinase Inhibitor

Key Eligibility Criteria:

Gender: Female
Age: 18 Years and older (Adult, Senior)
Location of Metastases: Brain
Additional Notes: 
Exclusions: Patients with symptomatic brain metastases; Previous therapy with T-DM1 or any HER2 tyrosine kinase inhibitor (TKI)
https://ClinicalTrials.gov/show/NCT02236000